Regional metabolic rate for glucose (rCMRGlc) was estimated using
positron emission tomography (PET) in five patients (four men, one woman; mean age 68; mean disease duration 2-4 years) with clinical findings consistent with the syndrome of cortico-basal ganglionic degeneration (CBGD). Left-right rCMRGlc asymmetry, (L -R)/(L + R) x 100, was calculated for 13 grey matter regions and compared with regional metabolic data from 18 normal volunteers and nine patients with asymmetrical Parkinson's disease (PD). In the CBGD group mean metabolic asymmetry values in the thalamus, inferior parietal lobule and hippocampus were greater than those measured in normal control subjects and patients with asymmetrical PD (p < 0 02). Parietal lobe asymmetry of 5% or more was evident in all CBGD patients, whereas in PD patients and normal controls, all regional asymmetry measures were less than 5% in absolute value. Measures of frontal, parietal and hemispheric metabolic asymmetry were found to be positively correlated with asymmetries in thalamic rCMRGlc (p < 0 05). The presence of cortico-thalamic metabolic asymmetry is consistent with the focal neuropathological changes reported in CBGD brains. Our findings suggest that metabolic asymmetries detected with FDG/PET may support a diagnosis of CBGD in life.
Cortico-basal ganglionic degeneration (CBGD) is an often misdiagnosed extrapyramidal syndrome characterised by progressive unilateral rigidity associated with lateralised cortical signs and involuntary movements."' While focal cortical findings (that is, limb apraxia, cortical sensory impairment, alien limb syndrome or cortical reflex myoclonus) are essential for diagnosis, other signs such as supranuclear gaze palsy, gait disturbance and action tremor may also be present."~Dementia, when evident, occurs only late in the clinical course. The motor manifestations of CBGD are typically refractory to levodopa and dopamine agonists. MRI and CT scans may be unrevealing early in the clinical course, although some degree of asymmetrical cerebral atrophy may develop as the disease progresses."
Although the presence of focal cortical dysfunction is necessary for the clinical diagnosis of CBGD, the extrapyramidal manifestations may dominate the presenting picture. Consequently, CBGD may be confused with typical early Parkinson's disease (PD) . In an effort to define metabolic parameters that might distinguish CBGD patients from PD patients in life, we used ['5F]fluorodeoxyglucose (FDG) and positron emission tomography (PET) to study patients with clinical signs suggestive of CBGD and compared the results with those reported by us previously in PD patients and normal volunteers.8
Methods
We studied five patients [four men and one woman, mean (SD) age 68 (5) years, mean disease duration 2 4 years] with clinical findings compatible with CBGD. The diagnosis of CBGD with neuronal achromasia was confirmed at necropsy in one of these patients (Patient 1). All patients presented with unilateral limb rigidity or tremor which progressed to involve the other limbs within three years of onset. At least two of the following lateralised cortical findings were present in each of the five patients: limb apraxia (4/5), cortical sensory impairment (4/5), and pyramidal signs (5/5). Intellectual decline was not evident in these patients, and there were no oculomotor abnormalities; motor symptoms were universally refractory to levodopa and dopamine agonists. Family histories were negative in all patients, and there was no history of drug exposure, head injury, encephalitis, or metabolic disease. Space-occupying lesions and cerebrovascular lesions were excluded with MRI and/or CT examinations.
CT scans in patients 1 and 5 showed mild asymmetrical fronto-parietal cortical atrophy. MRI in patient 3 showed symmetrical biparietal atrophy; MRI scans in the remaining two patients were normal. PET measurements in these patients were compared with values reported by us previously for a group of PD patients and normal control subjects.8 A summary of clinical data is provided in table 1. 4 This 68 year old right handed man developed difficulty manipulating a pen with his right hand three years before the study, followed by progressive difficulty in using his right hand. Over the next year he began dragging the right leg and fell repeatedly. His wife noticed that his speech was halting, and that he occasionally used the wrong words. The response to levodopa was poor. At the time of the study, he had mild, generalised bradykin-esia and rigidity, more pronounced on the right. He had continual groping movements with the right arm, which he was aware of, but could not suppress. There was marked apraxia and loss of graphaesthesia and stereognosis of the right hand with similar, but milder, difficulties on the left. Reflexes were increased on the right but both plantar reflexes were flexor. Speech was slow but of normal volume, and the mental status was unimpaired. An MRI scan was normal. Patient 5 This 75 year old man with a history of alcohol abuse and pernicious anaemia began falling and having difficulty using his right arm approximately one year before the study. He gradually developed a coarse postural and action tremor of the right arm. A trial of levodopa and bromocriptine was pursued without benefit. By the time ofthe study at the age of 76, he had generalised cogwheel rigidity and bradykinesia, most severe in the right arm, and an action tremor of both arms, much more severe on the right. In radiochemically pure (specific activity 500 mCi/ mmole). With the PC4600 positron camera,'0 serial PET images (10 x 1 min, 5 x 2 min, 3 x 5 min, 3 x 10 min) were obtained following the injection of 5-10 mCi of the tracer during a controlled resting state: eyes patched and auditory stimulation (music and intermittent verbal commands delivered through acoustically isolated earphones). The time course of plasma '8F radioactivity was determined by sampling radial arterial blood.
Region of interest (ROI) analysis was performed on 128 x 128 PET reconstructions that were corrected for random coincidences, electronic dead time and tissue attenuation. A single scalar correction was used to compensate for scatter effects in transmission, cross-calibration, and emission scans. Twenty four (12 per hemisphere) standardised cortical and subcortical grey matter (GM) ROIs and two cerebellar and two brainstem ROIs were outlined on reconstructed PET brain slices with reference to a neuroanatomical atlas." In four CBGD studies compartmental GM rate constants (k,-k3) and cerebral blood volume were estimated from the time course of blood and regional brain radioactivity.'2 To reduce noise, individual subjects' mean rate constants, averaged across GM ROIs, were used to "functionalise" raw-count images acquired between 45 and 55 minutes after tracer injection."" In the remaining study (patient 5), rCMRGlc was determined using average GM rate constants derived from the four dynamic FDG/PET studies. ' Mean metabolic asymmetry measures differed significantly between groups in each of the following brain regions: thalamus (p < 0 02), hippocampus/medial temporal cortex (p < 0-01), and the inferior parietal lobule (p < 0-0001). In each of these regions, mean asymmetry for the CBGD group was greater than that of normals or asymmetrical PD patients (fig 3) . Asymmetry measures in normal subjects and asymmetrical PD patients did not differ significantly. No significant between group differences in metabolic asymmetry were observed in other brain regions.
Individual metabolic asymmetry measures reached statistical significance (t tests) inconsistently in 4/5 of the CBGD patients studied. With the exception of the hippocampus/medial temporal region in patient 2 and the frontal operculum in patient 5, all significant metabolic asymmetries reflected reduced glucose metabolism contralateral to the most affected limbs. Parietal lobe asymmetry of 5% or more was evident in all CBGD patients, whereas in PD patients and in normal controls all regional asymmetry measures were less than 5% in absolute value. All parietal asymmetries reflected lower glucose metabolism contralateral to the most severely involved limbs. Hippocampal asymmetry exceeded 5% in the four patients in whom this region was identified; these asymmetries were directed opposite to the parietal lobe asymmetries.
Pairwise correlation of regional asymmetry measures revealed thalamic asymmetries to be positively correlated with metabolic asymmetries in the medial and lateral frontal cortex (r = 0-89; p < 0 05) and inferior parietal lobule (r = 0 90; p < 0 04), and with total hemispheric asymmetries (r = 090; p < 0-04). Parietal lobe asymmetries were found to be negatively correlated with metabolic asymmetries in the hippocampus (r = -0 99; p < 0-01). Other inter-regional asymmetry correlations in CBGD patients were not significant. We found no significant pairwise correlation between regional asymmetry measures in PD patients or normal subjects.
FDOPA/PET
An FDOPA/PET image (patient 2) at two hours post-injection is illustrated in fig 4. FDOPA uptake rate constants (Ki) for left and right striatum were (ROI 30) and the calcarine cortex (ROI 60) '26) . Moreover, some of the significant metabolic asymmetries, notably in the hippocampus (patient 2) and operculum and cerebellum (patient 5), indicated relative metabolic reductions ipsilateral to the more severely affected Metabolic asymmetries > 5% are underlined. Statistically significant differences in regional asymmetry between CBGD patients and 18 subjects are designated as: limbs. Whether these asymmetries reflect multiple foci of pathological involvement in the two hemispheres or remote functional consequences of disease in related brain regions is uncertain. The precise relevance of these metabolic asymmetries to the pathobiology of CBGD can be clarified only with the study ofmore patients and better necropsy correlations.
We did, however, find that the 5% threshold for regional metabolic asymmetries may be practical in differentiating the FDG/PET scans of CBGD suspects from normals and asymmetrical PD patients. As pathological entity, although they termed the illness corticodentatonigral degeneration after the loci of major histopathological change. In their three original patients, these authors (and subsequently others2-7) noted the presence of asymmetric gliosis and achromatic or pale neuronal inclusions in the parietal, posterior frontal and paracentral cortices, and in the substantia nigra-generally more pronounced contralateral to the more affected limbs. These morphological changes may be the substrate for the distinctive clinical manifestations and PET scan asymmetries reported here in living patients.
The finding of a significant positive correlation between cortical metabolic asymmetries, particularly in the inferior parietal lobule, and those occurring in the thalamus, reflects the close anatomical and functional relationship of these structures. The presence of uncrossed cortico-thalamic diaschisis in CBGD patients is consistent with the pathological finding of localised thalamic cell loss and gliosis, 26 29 have reported a correlation between cortical and thalamic metabolic asymmetries in Alzheimer's disease. Focal cortical hypometabolism and corticothalamic diaschisis may be evident in both CBGD and Alzheimer's disease, but these two entities are clearly distinguishable on clinical grounds-our patients presented with progressive lateralised motor dysfunction and not with intellectual decline. Furthermore, while some histopathological resemblance has been noted between CBGD and Pick's disease, the topography of the pathological6 and metabolic changes30 is quite different in the two diseases and suggest a major nosological distinction.
In conclusion, our FDG/PET findings, which are consistent with previous clinical and pathological descriptions of CBGD, may allow for the distinction of this entity from typical PD in life. Although the diagnosis of CBGD can only be confirmed at necropsy, the variety of histopathological changes found in the brains of patients with putative CBGD5 6 suggests that the clinical syndrome may have several neuropathological substrates. Thus, in addition to supporting the clinical diagnosis of CBGD, FDG/PET may also prove useful ante mortem insights into the metabolic pathologies which underlie this unusual illness.
